The United States has announced a 100% tariff on all branded and patented pharmaceutical imports from October 1, 2025, unless companies establish production facilities in the country. President Trump stated this move aims to boost domestic manufacturing and reduce the budget deficit. India, whose pharmaceutical exports to the U.S. reached $8.7 billion in 2023–24, could face significant costs and negative impacts on its drug exports. Analysts warn the policy may severely strain India’s pharmaceutical industry.
U.S. President Donald Trump has announced a 100% tariff on the import of branded and patented medicines. The tariff will come into effect from October 1. This decision has raised concerns that India’s pharmaceutical industry could be severely affected.
The ‘1 Nojor’ media platform is now live in beta, inviting users to explore and provide feedback as we continue to refine the experience.
